Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study-Reference-Cited by-同舟云学术

Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study

Published:2024-07 Issue:7 Volume:25 Page:853-864
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Van Laethem Jean-Luc,Borbath Ivan,Prenen Hans,Geboes Karen Paula,Lambert Aurélien,Mitry Emmanuel,Cassier Philippe Alexandre,Blanc Jean-Frédéric,Pilla Lorenzo,Batlle Jaime Feliu,Garrote Mercedes Rodriguez,Pazo-Cid Roberto Antonio,Gallego Inmaculada,Smith Karin Enell,Ellmark Peter,Pico de Coaña Yago,Ambarkhane Sumeet Vijay,Macarulla Teresa

Publisher

Elsevier BV

Reference30 articles.

1. Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up;Conroy;Ann Oncol,2023

2. Epidemiology of pancreatic cancer: global trends, etiology and risk factors;Rawla;World J Oncol,2019

3. Survival and prognostic factors of unresectable pancreatic cancer;Park;J Clin Gastroenterol,2008

4. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl J Med,2011

5. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug combinations of camptothecin derivatives promote the antitumor properties;European Journal of Medicinal Chemistry;2024-09

2. Small steps can lead to substantial breakthroughs: moving the therapeutic needle forward in pancreatic cancer;The Lancet Oncology;2024-07